Sort
23,748 grants matching “melanoma”
Combinational Immunotherapy Targeting the Melanoma-Associated Vasculature
$423,186Walter J Storkus · University Of Pittsburgh At Pittsburgh · R01 · FY2015 · CA
Combinational Immunotherapy Targeting the Melanoma-Associated Vasculature
$423,186Walter J Storkus · University Of Pittsburgh At Pittsburgh · R01 · FY2016 · CA
Defining therapeutic strategies for boosting T-cell infiltration into cold tumors with spatial proteomics and machine learning
$423,078Matthew W. Thomson · California Institute Of Technology · R21 · FY2023 · CA
Mechanisms of BAP1 activity in human cancer development
$423,075Michele Carbone · University Of Hawaii At Manoa · R01 · FY2021 · CA
Discovery and Clinical Validation of Cancer Biomarkers Using Printed Glycan Array
$423,001Margaret Elisabeth Huflejt · Cellexicon, Inc. · U01 · FY2007 · CA
Unraveling Vascular Mediated Immune Exclusion in Melanoma
$422,971Minah Kim · Columbia University Health Sciences · R21 · FY2024 · CA
SOUTHWEST ONCOLOGY GROUP CA-13612
$422,947University Of Arizona · U10 · FY2001 · CA
CALGB
$422,936Ohio State University · U10 · FY2000 · CA
Mechanisms of BAP1 activity in human cancer development
$422,917Michele Carbone · University Of Hawaii At Manoa · R01 · FY2024 · CA
Molecular Epidemiology of Non-Melanoma Skin Cancer
$422,853Harvard University (Sch Of Public Hlth) · R01 · FY2004 · CA
Discovery and Clinical Validation of Cancer Biomarkers Using Printed Glycan Array
$422,836Margaret Elisabeth Huflejt · New York University School Of Medicine · U01 · FY2009 · CA
Selective inhibition of nitric oxide synthase for multiple indications
$422,806Richard B Silverman · Northwestern University · R01 · FY2016 · GM
Transport Oncophysics Core
$422,589Haifa Shen · Methodist Hospital Research Institute · U54 · FY2020 · CA
Addressing Urban Rural Disparities in Cancer: The Case for Registry Expansion
$422,585Cathy J. Bradley · University Of Colorado Denver · R01 · FY2019 · CA
INTEGRATION OF CLINICAL, MOLECULAR, AND IMMUNE FEATURES TO IMPROVE RISK STRATIFICATION AND OUTCOMES IN MELANOMA PATIENTS WITH SENTINEL LYMPH NODE MET
$422,557The Univeristy Of Texas M.D. Anderson Cancer Center · · FY2018 · Defense Health Agency
ENHANCED MELANOMA VACCINE AGAINST NEOANTIGENS AND SHARED ANTIGENS BY CD40 ACTIVATION AND TLR AGONISTS
$422,524Rector & Visitors Of The University Of Virginia · · FY2019 · Defense Health Agency
Blood-based detection of BRAF and NRAS DNA as biomarkers in patients with stage I
$422,500David Polsky · New York University School Of Medicine · U01 · FY2011 · FD
Biogenesis of Melanosomes
$422,500Seth J. Orlow · New York University School Of Medicine · R01 · FY2010 · AR
Biogenesis of Melanosomes
$422,500Seth J. Orlow · New York University School Of Medicine · R01 · FY2009 · AR
Blood-based detection of BRAF and NRAS DNA as biomarkers in patients with stage I
$422,500David Polsky · New York University School Of Medicine · U01 · FY2012 · FD
Synergistic Targeting of the MAP Kinase Pathway in Melanoma
$422,464Ronen Marmorstein · Wistar Institute · P01 · FY2015 · CA
Eastern Cooperative Oncology Group Studies
$422,458Case Western Reserve University · U10 · FY2004 · CA
Structural Biology of GTPase Activating Proteins
$422,446R Byrd · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
HLA II PRESENTATION OF ANTIGENS FOR VACCINE
$422,289Rongfu Wang · University Of Tx Md Anderson Can Ctr · P50 · FY2007 · CA
EASTERN COOPERATIVE ONCOLOGY GROUP
$422,179University Of Pennsylvania · U10 · FY2003 · CA